Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD

被引:27
|
作者
Ben-Shimol, S. [1 ,2 ]
Greenberg, D. [1 ,2 ]
Givon-Lavi, N. [1 ,2 ]
Schlesinger, Y. [1 ,3 ]
Miron, D. [4 ]
Aviner, S. [5 ]
Dagan, R. [2 ]
机构
[1] Soroka Univ, Med Ctr, Pediat Infect Dis Unit, Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel
[3] Shaare Zedek Med Ctr, Pediat Infect Dis Unit, Jerusalem, Israel
[4] Emek Med Ctr, Pediat Infect Dis Serv, Afula, Israel
[5] Barzilai Univ, Med Ctr, Dept Pediat, Ashqelon, Israel
关键词
PCV7; PCV13; IPD; Children; Meningitis; Impact; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; 7-VALENT; CARRIAGE; ISRAEL; PCV13;
D O I
10.1016/j.vaccine.2016.07.038
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The worldwide introduction of pneumococcal conjugate vaccines (PCV) into National Immunization Programs resulted in rapid and substantial reduction of invasive pneumococcal disease (IPD) rates in children. However, the reduction of meningitis vs. non-meningitis IPD (nm-IPD) was not yet fully elucidated. We compared 7-valent and 13-valent PCV (PCV7 and PCV13) impact on pneumococcal-meningitis vs. nm-IPD in Israeli children <5 years. Methods: We conducted an ongoing nationwide, prospective, population-based, active surveillance. PCV7 and PCV13 were implemented in Israel in July 2009 and November 2010, respectively. All pneumococcal isolates (blood and/or CSF) from IPD episodes in children <5 years from July 2000 through June 2015 were included. Extrapolation for missing serotypes (34.7% of all isolates) was conducted. Results: 4163 IPD cases were identified; 3739 nm-IPD (89.8%) and 424 meningitis (10.2%). During the pre-PCV period (2000-2008), children <12 months constituted 52.1% and 33.7% of meningitis and nm-IPD, respectively (p < 0.001). The respective proportions of non-PCV13 serotypes (non-VT) were 18.2% vs. 10.1%, (p < 0.001). Comparing the last study year (2014-2015) to the mean of pre-PCV period, meningitis incidence in children <5 years decreased non-significantly by 27%, while nm-IPD decreased significantly by 69%. Dynamic rates of meningitis and nm-IPD caused by PCV13 serotypes were similar, with 93% and 95% overall reductions, respectively. However, non-VT increased in meningitis relatively to nm-IPD, mainly in children <24 months. Serotype 12F rose sharply and significantly since 2009-2010 through 2014-2015 (28.6% of all non-VT meningitis in children <24 m). Conclusions: The overall impact of PCV7/PCV13 in children <5 years in Israel was less prominent in meningitis than in nm-IPD. This could be attributed to the younger age of children with meningitis and differences in causative serotypes between the two groups, as the decline of the incidence of meningitis and nm-IPD caused by vaccine-serotypes is similar. Continuous monitoring of meningitis and nm-IPD is warranted. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4543 / 4550
页数:8
相关论文
共 50 条
  • [21] Invasive Disease Potential of Pneumococcal Serotypes in Children After PCV13 Implementation
    Cohen, Robert
    Levy, Corinne
    Ouldali, Naim
    Goldrey, Marie
    Bechet, Stephane
    Bonacorsi, Stephane
    Varon, Emmanuelle
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (08) : 1453 - 1456
  • [22] The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel
    Regev-Yochay, Gili
    Katzir, Michal
    Strahilevitz, Jacob
    Rahav, Galia
    Finn, Talya
    Miron, Dan
    Maor, Yasmin
    Chazan, Bibiana
    Schindler, Yehudith
    Dagan, Ron
    VACCINE, 2017, 35 (18) : 2449 - 2456
  • [23] HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV)
    Meiring, Susan
    Cohen, Cheryl
    Quan, Vanessa
    de Gouveia, Linda
    Feldman, Charles
    Karstaedt, Alan
    Klugman, Keith P.
    Madhi, Shabir A.
    Rabie, Helene
    Sriruttan, Charlotte
    von Gottberg, Anne
    PLOS ONE, 2016, 11 (02):
  • [24] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants
    Grimprel, E.
    Laudat, F.
    Patterson, S.
    Baker, S. A.
    Sidhu, M. S.
    Gruber, W. C.
    Emini, E. A.
    Scott, D. A.
    VACCINE, 2011, 29 (52) : 9675 - 9683
  • [25] Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska
    Bruce, Michael G.
    Singleton, Rosalyn
    Bulkow, Lisa
    Rudolph, Karen
    Zulz, Tammy
    Gounder, Prabhu
    Hurlburt, Debby
    Bruden, Dana
    Hennessy, Thomas
    VACCINE, 2015, 33 (38) : 4813 - 4819
  • [26] Towards the 13-valent pneumococcal conjugate universal vaccination Effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013
    Martinelli, Domenico
    Pedalino, Biagio
    Cappelli, Maria Giovanna
    Caputi, Giovanni
    Sallustio, Anna
    Fortunato, Francesca
    Tafuri, Silvio
    Cozza, Vanessa
    Germinario, Cinzia
    Chironna, Maria
    Prato, Rosa
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (01) : 33 - 39
  • [27] 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): A phase 3, open-label trial
    Silfverdal, Sven Arne
    Flodmark, Carl-Erik
    Rombo, Lars
    Tansey, Susan P.
    Sidhu, Mohinder
    Trammel, James
    Emini, Emilio A.
    Gruber, William C.
    Scott, Daniel A.
    Gurtman, Alejandra
    VACCINE, 2013, 31 (09) : 1284 - 1292
  • [28] Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
    Tomczyk, Sara
    Lessa, Fernanda C.
    Sanchez, Jacqueline
    Pena, Chabela
    Fernandez, Josefina
    Carvalho, M. Gloria
    Pimenta, Fabiana
    Cedano, Doraliza
    Whitney, Cynthia G.
    Verani, Jennifer R.
    Coradin, Hilma
    Garib, Zacarias
    De Oliveira, Lucia Helena
    Feris-Iglesias, Jesus
    BMC INFECTIOUS DISEASES, 2018, 18
  • [29] Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
    Sara Tomczyk
    Fernanda C. Lessa
    Jacqueline Sánchez
    Chabela Peña
    Josefina Fernández
    M. Gloria Carvalho
    Fabiana Pimenta
    Doraliza Cedano
    Cynthia G. Whitney
    Jennifer R. Verani
    Hilma Coradin
    Zacarías Garib
    Lucia Helena De Oliveira
    Jesús Feris-Iglesias
    BMC Infectious Diseases, 18
  • [30] Invasive Pneumococcal Disease in Infants Younger Than 90 Days Before and After Introduction of PCV7
    Olarte, Liset
    Ampofo, Krow
    Stockmann, Chris
    Mason, Edward O.
    Daly, Judy A.
    Pavia, Andrew T.
    Byington, Carrie L.
    PEDIATRICS, 2013, 132 (01) : E17 - E24